Resumen: Objectives: Extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-E. coli) are a main cause of human deaths associated with antimicrobial resistance (AMR). Despite hundreds of reports of the faecal carriage of ESBL-E. coli in domestic and wild animals, the dynamics of its circulation remains poorly understood. Methods: We used whole genome sequencing of 19 ESBL-E. coli previously isolated in the same local setting from dogs, livestock, and a wild rodent in Central Chile to assess potential cross-species transmission of ESBL-E. coli. Results: Isolates harboured a large number of AMR (n = 95) and virulence (n = 45) genes, plasmids replicons (n = 24), and E. coli sequence types including top extraintestinal pathogenic E. coli ST410, ST58, ST88, and ST617. Almost identical clones (<50 single nucleotide polymorphisms difference, same antibiotic and heavy metal resistance genes, virulence genes, and plasmids) were found in faeces of dogs, cattle, or sheep from the same farm, and in a dog and a wild rodent living in proximity. Conclusions: To our knowledge, this is the first report of multiple clonal cross-species transmission of ESBL-E. coli in domestic and potentially wild animals of Latin America. Our results suggest that relatively rare spread of AMR across animal species can still occur by both clonal and plasmid dissemination. Our study highlights the need for establishing preventive measures to limit the circulation of these bacteria among animals in agricultural settings, particularly given the highly pathogenic profile of several E. coli strains detected in these animals. Idioma: Inglés DOI: 10.1016/j.jgar.2023.07.009 Año: 2023 Publicado en: Journal of global antimicrobial resistance 34 (2023), 247-252 ISSN: 2213-7165 Factor impacto JCR: 3.7 (2023) Categ. JCR: PHARMACOLOGY & PHARMACY rank: 90 / 354 = 0.254 (2023) - Q2 - T1 Categ. JCR: INFECTIOUS DISEASES rank: 39 / 132 = 0.295 (2023) - Q2 - T1 Factor impacto CITESCORE: 8.7 - Microbiology (medical) (Q1) - Microbiology (Q1) - Immunology and Allergy (Q2) - Immunology (Q2)